A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis
Key PointsThe overall response rate for low-dose subcutaneous decitabine was 33% in this prospective clinical trial of 21 patients with myelofibrosis.A hig
Related Articles
What RFK Jr. Gets Right—and What He Gets Wrong
Dr. Vinay Prasad fact-checks the presidential candidate on vaccines, regulatory capture, and more.
Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study
Over nearly 2·5 years, most lives saved by COVID-19 vaccination were in older adults by first booster dose and during the Omicron period, reinforcing the…
Btk inhibition: the importance of being selective
First generation Bruton’s tyrosine kinase (Btk) inhibitors were associated with both decreased thrombosis and increased bleeding. However, newer more selec
Trust in science hasn’t fully recovered from pandemic controversies
Despite a slight uptick in trust, scientists continue to face challenges in regaining public trust after the pandemic.
2025 GOLD Report – Global Initiative for Chronic Obstructive Lung Disease – GOLD
The FINAL VERSION OF THE GOLD REPORT WILL BE MADE AVAILABLE THE WEEK OF November 11th GLOBAL STRATEGY FOR PREVENTION, DIAGNOSIS AND MANAGEMENT OF COPD:…
Four Tech Scale-Ups Win Unicorn Pathfinder Awards
The UK Government has announced four tech scale up businesses as winners of the Unicorn Kingdom Pathfinder Awards.
Consumer Wearables—Advancing Atrial Fibrillation Care or Too Much Information?
This Viewpoint describes the diffusion of direct-to-consumer wearable devices capable of early atrial fibrillation detection and the unclear implications for initiation of anticoagulation therapy based…
Optical coherence tomography predictors of clinical outcomes after stent implantation: the ILUMIEN IV trial
AbstractBackground and Aims. Observational registries have suggested that optical coherence tomography (OCT) imaging-derived parameters may predict adverse
Myeloma Paper of the Day, November 14th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, November 14th, suggested by Robert Orlowski / Ali Bazarbachi, allogeneic transplant, cancer, Carmelo Gurnari, Christof Scheid,
